Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Performance of the Dosage of Plasma 1, 3-β-D-glucan (BDG) for the Diagnosis of Candidemia in Intensive Care Patients: A Prospective, Multicenter Study

NCT03674359 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT03674359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03674359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Performance of the Dosage of Plasma 1, 3-β-D-glucan (BDG) for the Diagnosis of Candidemia in Intensive Care Patients: A Prospective, Multicenter Study
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Unknown status
Start date
December 12, 2018
Completion date
March 31, 2022
Enrollment
2,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

infection, fungal